Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology

详细信息    查看全文

• 作者：Matteo Lambertini^a ; ^b ; ^{matteo.lambertini85@gmail.com} ; Michela Cinquini^c ; ^{michela.cinquini@marionegri.it} ; Ivan Moschetti^c ; ^{ivan.moschetti@marionegri.it} ; Fedro A. Peccatori^d ; ^{fedro.peccatori@ieo.it} ; Paola Anserini^e ; ^{paola.anserini@fastwebnet.it} ; Mario Valenzano Menada^f ; ^{sasmario@unige.it} ; Maurizio Tomirotti^g ; ^{maurizio.tomirotti@policlinico.mi.it} ; Lucia Del Mastro^h ; ^{lucia.delmastro@hsanmartino.it}
• 关键词：Premature ovarian failure ; Breast cancer ; Luteinising hormone-releasing hormone analogues (LHRHa) ; Fertility preservation ; Italian Association of Medical Oncology (AIOM) ; Grades of Recommendation ; Assessment ; Development ; and Evaluation (GRADE)
• 刊名：European Journal of Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：71
• 期：Complete
• 页码：25-33
• 全文大小：540 K
• 卷排序：71

文摘

Treatment-induced ovarian function loss is of great concern for young breast cancer patients. The protective role of luteinising hormone-releasing hormone analogues (LHRHa) during chemotherapy has been highly debated in the last years. Grades of Recommendation, Assessment, Development and Evaluation approach by the Italian Association of Medical Oncology (AIOM) to investigate this issue. The Panel of the AIOM Clinical Practice Guideline recommends the use of LHRHa during chemotherapy.